HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS)

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $7.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on the company. StockNews.com downgraded Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Stock Down 4.4 %

Atossa Therapeutics stock opened at $0.69 on Wednesday. The company’s 50-day moving average price is $0.83 and its 200-day moving average price is $1.15. The company has a market cap of $86.22 million, a PE ratio of -3.12 and a beta of 1.20. Atossa Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.31.

Institutional Trading of Atossa Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC grew its holdings in shares of Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after purchasing an additional 123,683 shares during the last quarter. State Street Corp lifted its stake in shares of Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after buying an additional 69,180 shares during the period. XTX Topco Ltd raised its stake in shares of Atossa Therapeutics by 101.2% in the third quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock worth $75,000 after purchasing an additional 24,951 shares during the last quarter. Geode Capital Management LLC increased its holdings in Atossa Therapeutics by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock worth $4,278,000 after buying an additional 44,762 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Atossa Therapeutics by 177.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock worth $227,000 after buying an additional 95,643 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.